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Aims: Canagliﬂozin, a sodium glucose co-transporter 2 inhibitor, has demonstrated glycemic improvements
across studies of patients with type 2 diabetes mellitus (T2DM). The impact of canagliﬂozin on HbA1c
lowering was assessed by baseline HbA1c and known duration of T2DM.
Methods: This post hoc analysis pooled data from patients with T2DM enrolled in four 26-week,
placebo-controlled, Phase 3 studies of canagliﬂozin (N = 2313). Change in HbA1c from baseline to Week 26
was assessed in the overall population and in subgroups by baseline HbA1c (b8.0%, 8.0%–b9.0%, and ≥9.0%) and
known duration of T2DM (b5 years, 5–b10 years, and ≥10 years).
Results: Relative to placebo, canagliﬂozin 100 and 300 mg provided greater HbA1c reductions in the overall
population. Progressively larger placebo-subtracted reductions in HbA1c with canagliﬂozin 100 and 300 mg
were seen with increasing baseline HbA1c. HbA1c reductions were similar across subgroups based on known
duration of T2DM. Both canagliﬂozin doses were generally well tolerated across subgroups, with a safety and
tolerability proﬁle consistent with that seen in Phase 3 studies.
Conclusions: Canagliﬂozin provided glycemic improvements in patients with T2DM across a range of baseline
HbA1c and known duration of T2DM.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Type 2 diabetes mellitus (T2DM) is a chronic disease that develops
as a result of defective insulin secretion and is frequently associated
with obesity-related insulin resistance (Defronzo, 2010). T2DM is also
characterized by progressively decreased beta-cell function over time
(Inzucchi et al., 2012; Jabbour, 2008; Standl, 2007). Glucose-lowering
agents are regularly implemented to manage hyperglycemia when
lifestyle modiﬁcations (eg, diet and exercise) are insufﬁcient
(American Diabetes Association, 2014; Inzucchi et al., 2012).
Underlying disease progression leads to treatment intensiﬁcation
with combination therapy, and ultimately insulin therapy is oftenCT01081834; NCT01106625;
d Endocrinology, Institute of
, University Hospital Aintree,
: +44 151 529 5885; fax: +44
Wilding).
Inc. This is an open access article uinitiated (Cook, Girman, Stein, & Alexander, 2007; Cook, Girman,
Stein, Alexander, & Holman, 2005; Inzucchi et al., 2012). The efﬁcacy
of glucose-lowering treatments has been shown to be impacted by
baseline HbA1c, with greater reductions in HbA1c generally observed
in patients with higher baseline HbA1c (Bloomgarden, Dodis, Viscoli,
Holmboe, & Inzucchi, 2006).
In individuals with hyperglycemia, plasma glucose levels can be
lowered by inhibiting sodium glucose co-transporter 2 (SGLT2), a
low-afﬁnity, high-capacity glucose transporter that is responsible for
the majority of renal glucose reabsorption (Wright, Loo, & Hirayama,
2011). Canagliﬂozin is an SGLT2 inhibitor developed for the treatment
of adults with T2DM (Janssen Pharmaceuticals, 2014). Canagliﬂozin
lowers the renal threshold for glucose (RTG), thereby promoting
urinary glucose excretion (UGE; ~80–120 g/day) (Devineni et al.,
2013; Devineni et al., 2012; Polidori et al., 2013; Rosenstock et al.,
2012; Sha et al., 2014). Increased UGE leads to a mild osmotic diuresis
and a net caloric loss that may lead to reductions in body weight and
blood pressure. In addition, there is a low inherent risk of
hypoglycemiawith canagliﬂozin treatment, making it complementarynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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canagliﬂozin improved glycemic control, reduced body weight and
systolic blood pressure, and was generally well tolerated in a broad
range of patients with T2DM inadequately controlled by their current
treatment regimens (Bode, Stenlöf, Sullivan, Fung, & Usiskin, 2013;
Cefalu et al., 2013; Forst et al., 2014; Lavalle-González et al., 2013;
Leiter et al., 2014; Schernthaner et al., 2013; Stenlöf et al., 2013;
Stenlöf et al., 2014; Wilding et al., 2013; Yale et al., 2013; Yale et al.,
2014). Therefore, canagliﬂozin treatment may be beneﬁcial for a
broad range of patients across different stages of T2DM.
Baseline HbA1c and duration of T2DM are patient disease character-
istics known to potentially impact the efﬁcacy of glucose-lowering
treatments. In this analysis, the effects of canagliﬂozin on HbA1c, by
baseline HbA1c and known duration of T2DM, were assessed based on
pooleddata from four 26-week, double-blind, placebo-controlled, Phase
3 studies in patients with T2DM (Forst et al., 2014; Lavalle-González et
al., 2013; Stenlöf et al., 2013; Wilding et al., 2013).
2. Methods
2.1. Study design and patients
This post hoc analysis was based on pooled data from patients
with T2DM (N = 2313) enrolled in four 26-week, double-blind,
placebo-controlled, Phase 3 studies [monotherapy (Stenlöf et al.,
2013), add-on to metformin (Lavalle-González et al., 2013), add-on
to metformin plus sulfonylurea (Wilding et al., 2013), and add-on to
metformin plus pioglitazone (Forst et al., 2014)]. Patients were
randomized to receive canagliﬂozin 100 and 300 mg or placebo once
daily during a 26-week core treatment period, followed by a 26-week
extensionperiod. Data from the26-week core treatment periods of each
study were included in this pooled analysis; the high glycemic subset
(HbA1c N10.0%–≤12.0%) of the monotherapy study, which was not
placebo-controlled, and the sitagliptin arm of the add-on to metformin
study, which was not prespeciﬁed for efﬁcacy comparisons versus
canagliﬂozin at Week 26, were excluded from this analysis.
Key inclusion and exclusion criteria are shown in Table 1. In each
study, eligible patients who were on protocol-speciﬁed background
glucose-lowering treatment entered into a 2-week, placebo run-in
period. Patients who were not on the protocol-speciﬁed background
glucose-lowering treatment (n = 821 [35.5%]) entered an 8- to
12-week adjustment/dose stabilization period prior to the placeboTable 1
Study design and patient populationa.
Inclusion criteriab Patients contributing data
to pooled analysis, n
Study Age, y HbA1c, % eGFR, mL/
min/1.73 m2
PBO CANA
100 mg
CANA
300 mg
Total
Monotherapy 18–80 7.0–10.0 ≥50 192 195 197 584
Add-on to
MET
18–80 7.0–10.5 ≥55 183 368 367 918
Add-on to
MET + SU
18–80 7.0–10.5 ≥55 156 157 156 469
Add-on to
MET + PIO
18–80 7.0–10.5 ≥55 115 113 114 342
Overall total, N 646 833 834 2313
eGFR, estimated glomerular ﬁltration rate; PBO, placebo; CANA, canagliﬂozin; MET,
metformin; SU, sulfonylurea; PIO, pioglitazone; FPG, fasting plasma glucose; ULN,
upper limit of normal.
a Data have been previously reported (Usiskin, Kline, Fung, Mayer, & Meininger, 2014).
b Key exclusion criteria common to the 4 studies included repeated FPG generally
≥15.0 mmol/L during the pretreatment phase; history of diabetic ketoacidosis or
type 1 diabetes; history of myocardial infarction, unstable angina, revascular-
ization procedure, or cerebrovascular accident with 3 months of screening;
uncontrolled hypertension; and alanine aminotransferase level N2 times the ULN
or total bilirubin N1.5 times the ULN at screening.run-in period. Patients were required to remain on their stable
diabetes treatment regimen throughout the entire double-blind
period. Randomization (1:1:1) to study drug (canagliﬂozin 100 or
300 mg or placebo) was stratiﬁed using permuted blocks to ensure
adequate distribution of patient characteristics relevant to each study
(eg, whether a patient entered the adjustment/dose stabilization
period, participation in a mixed-meal tolerance test, pioglitazone
dose). After randomization, HbA1c and fasting plasma glucose (FPG)
values weremasked to the study centers unless predeﬁned criteria for
glycemic rescue were met. Glycemic rescue therapy was initiated
when FPG was N15.0 mmol/L after Day 1 to Week 6, N13.3 mmol/L
afterWeek 6 toWeek 12, and N11.1 mmol/L afterWeek 12 toWeek 26
using a glucose-lowering agent selected to be complementary to the
protocol-speciﬁed background therapy. In each study, the patients,
study center, sponsor, and local sponsor personnel remained blinded
throughout the 26-week treatment period.
These studies were conducted in accordance with the ethical
principles originating in the Declaration of Helsinki andwere consistent
with Good Clinical Practices and applicable regulatory requirements.
Approval was obtained from institutional review boards and indepen-
dent ethics committees for participating centers, and written informed
consent was provided by patients prior to participation.
2.2. Study endpoints and assessments
The primary endpoint of each study was the change from baseline
in HbA1c at Week 26. For this post hoc analysis, changes from baseline
in HbA1c at 26 weeks were evaluated in the overall pooled population
and in subgroups of patients by baseline HbA1c (b8.0% [n = 1218],
8.0%–b9.0% [n = 712], and ≥9.0% [n = 383]) and known duration of
T2DM (b5 years [n = 936], 5–b10 years [n = 709], and ≥10 years
[n = 668]). The proportion of patients with HbA1c b7.0% at Week 26
was also assessed in subgroups by baseline HbA1c and known duration
of T2DM.
Safety and tolerability were assessed based on adverse event (AE)
reports, safety laboratory tests, 12-lead electrocardiograms, vital sign
measurements, physical examinations, and self-monitored blood
glucose. The incidence of selected AEs, including genital mycotic
infections, urinary tract infections, and AEs related to osmotic diuresis
and volume depletion, was also evaluated. Documented hypoglyce-
mia episodes included biochemically conﬁrmed episodes (concurrent
ﬁngerstick or plasma glucose ≤3.9 mmol/L, with or without symp-
toms) and severe episodes (ie, those requiring the assistance of
another individual or resulting in seizure or loss of consciousness).
2.3. Statistical analyses
Efﬁcacy analyses were conducted using the modiﬁed intent-to-
treat (mITT) population, consisting of all randomized patients who
received ≥1 dose of double-blind study drug. The last observation
carried forward (LOCF) approach was used to impute missing data at
Week 26. For patients who received glycemic rescue therapy, the last
post-baseline value prior to the initiation of rescue therapy was used
for the efﬁcacy analysis. Continuous endpoints were assessed using
an analysis of covariance (ANCOVA) model, with treatment and
study as factors and the respective baseline value as a covariate. Least
squares (LS) means and 95% conﬁdence intervals (CIs) were
estimated for the comparisons of each canagliﬂozin dose with
placebo. Odds ratios and 95% CIs were calculated for the proportion
of patients achieving HbA1c b7.0% with canagliﬂozin versus placebo
in the subgroups by baseline HbA1c and known duration of T2DM at
Week 26. Statistical testing of canagliﬂozin versus placebo was not
prespeciﬁed for analyses of efﬁcacy parameters in these post hoc
analyses. Therefore, no P values are reported; however, 95% CIs are
reported for descriptive purposes.
Fig. 1. Change in HbA1c in the overall population (LOCF). LOCF, last observation carried
forward; LS, least squares; SE, standard error; CI, conﬁdence interval; PBO, placebo;
CANA, canagliﬂozin.
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3.1. Patients
Of the 2313 patients in the mITT population, 1984 (85.8%)
completed the 26-week treatment period. Baseline demographic
and disease characteristics were generally similar across treatment
groups in the overall population (Table 2) and in subgroups by
baseline HbA1c (Supplementary Table 1) and known duration of
T2DM (Supplementary Table 2). Patients with higher baseline HbA1c
generally had longer known duration of T2DM. Patients with longer
known duration of T2DM at baseline generally were older and had
lower baseline eGFR values, but had similar baseline HbA1c compared
with patients with shorter known duration of T2DM.
3.2. Efﬁcacy
At Week 26, canagliﬂozin 100 and 300 mg provided dose-related
reductions from baseline in HbA1c compared with placebo (Fig. 1).
Across baseline HbA1c subgroups, patients in both canagliﬂozin
groups had larger dose-dependent reductions in HbA1c compared
with patients in the placebo group (Fig. 2A). Placebo-subtracted LS
mean reductions at Week 26 with canagliﬂozin 100 and 300 mg were
progressively larger with increasing baseline HbA1c, with the largest
reductions in HbA1c observed in patients with the greatest degree of
hyperglycemia at baseline. Compared with placebo, a greater
proportion of patients achieved HbA1c b7.0% with canagliﬂozin 100
and 300 mg across subgroups by baseline HbA1c; the odds of
achieving HbA1c b7.0% favored both canagliﬂozin doses versus
placebo across HbA1c subgroups (Fig. 2B). The proportion of patients
who achieved HbA1c b7.0% with canagliﬂozin 100 and 300 mg versus
placebo was highest in patients with baseline HbA1c b8.0% compared
with those who had baseline HbA1c 8.0%–b9.0% and HbA1c ≥9.0%.
Reductions in HbA1c with canagliﬂozin 100 and 300 mg were
similar across subgroups by known T2DM duration (Fig. 2C). The
proportion of patients achieving HbA1c b7.0% was greater with
canagliﬂozin 100 and 300 mg compared with placebo across
subgroups by known duration of T2DM; the odds of achieving
HbA1c b7.0% favored canagliﬂozin 100 and 300 mg versus placebo
across subgroups by known T2DM duration (Fig. 2D).Table 2
Baseline demographic and disease characteristics in the overall populationa,b.
Characteristic PBO
(n = 646)
CANA 100 mg
(n = 833)
CANA 300 mg
(n = 834)
Total
(N = 2313)
Sex, n (%)c
Male 334 (52) 408 (49) 404 (48) 1146 (50)
Female 312 (48) 425 (51) 430 (52) 1167 (51)
Age, y 56.3 (9.8) 55.9 (10.1) 55.7 (9.5) 56.0 (9.8)
Race, n (%)c
White 470 (73) 591 (71) 610 (73) 1671 (72)
Black or African
American
28 (4) 43 (5) 48 (6) 119 (5)
Asian 82 (13) 103 (12) 100 (12) 285 (12)
Otherd 66 (10) 96 (12) 76 (9) 238 (10)
HbA1c, % 8.0 (0.9) 8.0 (0.9) 8.0 (1.0) 8.0 (0.9)
BMI, kg/m2 31.9 (6.4) 32.3 (6.4) 32.0 (6.5) 32.1 (6.4)
eGFR, mL/min/
1.73 m2
87.0 (19.8) 88.3 (19.0) 88.8 (18.9) 88.1 (19.2)
Duration of
T2DM, y
7.5 (6.2) 7.2 (5.8) 7.4 (6.2) 7.3 (6.0)
PBO, placebo; CANA, canagliﬂozin; BMI, body mass index; eGFR, estimated glomerular
ﬁltration rate; T2DM, type 2 diabetes mellitus; SD, standard deviation.
a Data have been previously reported (Usiskin et al., 2014).
b Data are mean (SD) unless otherwise indicated.
c Percentages may not total 100% due to rounding.
d Includes American Indian or Alaska Native, Native Hawaiian or other Paciﬁc
Islander, multiple, other, unknown, and not reported.3.3. Safety
The incidence of AEs was similar with canagliﬂozin 100 and 300 mg
and placebo in the overall population; AE-related study discontinua-
tions were low across groups, but slightly higher with canagliﬂozin
compared with placebo (Supplementary Table 3) (Usiskin et al., 2014).
Incidences of genital mycotic infections and AEs related to osmotic
diuresis (eg, pollakiuria [increased urine frequency], polyuria [increased
urine volume]) were higher with canagliﬂozin 100 and 300 mg relative
to placebo, and incidences of volume depletion–related AEs (eg,
orthostatic hypotension, postural dizziness) were low and similar
across treatment groups. The incidence of urinary tract infections was
similar across groups; 40.0% and 23.1% of patients who reported a
urinary tract infection AE in the combined canagliﬂozin group and the
placebogroup, respectively, had conﬁrmeddiagnoses (Nicolle, Capuano,
Fung, & Usiskin, 2014).
In subgroups by baseline HbA1c, the incidence of AEs was generally
similar to that seen in the overall population, with a low incidence of
AE-related discontinuations (b5%) across treatment groups in all
subgroups (Table3). Across subgroupsbybaselineHbA1c, the incidences
of male and female genital mycotic infections were higher with
canagliﬂozin 100 and 300 mg compared with placebo. There was no
discernable trend in the incidence of male genital mycotic infections
related to baseline HbA1c; however, female genital mycotic infections
were more common in patients with HbA1c ≥9.0% versus those with
lower baselineHbA1c. The incidence of osmoticdiuresis–relatedAEswas
also higher in patients treated with canagliﬂozin versus placebo among
thosewho had baseline HbA1c≥9.0% comparedwith those in the lower
baseline HbA1c subgroups. Consistent with the overall population, the
incidence of volume depletion–related AEs was low and similar across
subgroups. The incidence of documented hypoglycemia episodes
(concurrent ﬁngerstick or plasma glucose ≤3.9 mmol/L, with or
without symptoms) was evaluated separately according to baseline
use of glucose-lowering agents associated with hypoglycemia (ie,
sulfonylurea). The incidence of documented hypoglycemia episodes
Fig. 2. Change in HbA1c and proportion of patients with HbA1c b7.0% atWeek 26 in subgroups by baseline HbA1c (A, B) and known duration of T2DM (C, D) (LOCF). T2DM, type 2 diabetes mellitus; LOCF, last observation carried forward;
LS, least squares; SE, standard error; CI, conﬁdence interval; PBO, placebo; CANA, canagliﬂozin; OR, odds ratio.
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Table 3
Summary of overall safety and speciﬁc AEs in subgroups by baseline HbA1c.
HbA1c b8.0% HbA1c 8.0%–b9.0% HbA1c ≥9.0%
Patients, n (%) PBO
(n = 355)
CANA 100 mg
(n = 425)
CANA 300 mg
(n = 438)
PBO
(n = 179)
CANA 100 mg
(n = 272)
CANA 300 mg
(n = 261)
PBO
(n = 112)
CANA 100 mg
(n = 136)
CANA 300 mg
(n = 135)
Any AE 215 (60.6) 265 (62.4) 249 (56.8) 101 (56.4) 157 (57.7) 163 (62.5) 68 (60.7) 79 (58.1) 82 (60.7)
AEs leading to discontinuation 14 (3.9) 18 (4.2) 18 (4.1) 4 (2.2) 12 (4.4) 7 (2.7) 2 (1.8) 6 (4.4) 5 (3.7)
AEs related to study druga 55 (15.5) 80 (18.8) 104 (23.7) 19 (10.6) 61 (22.4) 56 (21.5) 11 (9.8) 30 (22.1) 31 (23.0)
Serious AEs 13 (3.7) 11 (2.6) 11 (2.5) 5 (2.8) 12 (4.4) 8 (3.1) 4 (3.6) 5 (3.7) 3 (2.2)
Deaths 2 (0.6) 1 (0.2) 1 (0.2) 0 0 0 0 0 0
Genital mycotic infection
Maleb,c 0 6 (3.1) 7 (3.6) 1 (1.1) 8 (5.9) 5 (4.0) 1 (1.7) 3 (3.8) 3 (3.6)
Femaled,e 6 (3.4) 22 (9.5) 28 (11.6) 2 (2.4) 13 (9.6) 12 (8.8) 2 (3.8) 9 (15.5) 9 (17.3)
UTI 17 (4.8) 26 (6.1) 17 (3.9) 6 (3.4) 17 (6.3) 14 (5.4) 3 (2.7) 6 (4.4) 5 (3.7)
Osmotic diuresis–related AEsf 5 (1.4) 24 (5.6) 19 (4.3) 0 19 (7.0) 18 (6.9) 0 13 (9.6) 10 (7.4)
Volume depletion–related AEsg 3 (0.8) 7 (1.6) 3 (0.7) 3 (1.7) 3 (1.1) 5 (1.9) 1 (0.9) 0 3 (2.2)
AE, adverse event; PBO, placebo; CANA, canagliﬂozin; UTI, urinary tract infection.
a Possibly, probably, or very likely related to study drug, as assessed by investigators.
b HbA1c b8.0%: PBO, n = 180; CANA 100 mg, n = 194; CANA 300 mg, n = 197; HbA1c 8.0%–b9.0%: PBO, n = 95; CANA 100 mg, n = 136; CANA 300 mg, n = 124; HbA1c≥9.0%:
PBO, n = 59; CANA 100 mg, n = 78; CANA 300 mg, n = 83.
c Including balanitis, balanitis candida, balanoposthitis, and genital infection fungal.
d HbA1c b8.0%: PBO, n = 175; CANA 100 mg, n = 231; CANA 300 mg, n = 241; HbA1c 8.0%–b9.0%: PBO, n = 84; CANA 100 mg, n = 136; CANA 300 mg, n = 137; HbA1c≥9.0%:
PBO, n = 53; CANA 100 mg, n = 58; CANA 300 mg, n = 52.
e Including genital infection fungal, vaginal infection, vulvitis, vulvovaginal candidiasis, vulvovaginal mycotic infection, and vulvovaginitis.
f Including dry mouth, micturition urgency, nocturia, pollakiuria, polydipsia, polyuria, thirst, and urine output increased.
g Including blood pressure decreased, dehydration, dizziness postural, hypotension, orthostatic hypotension, orthostatic intolerance, presyncope, and syncope.
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among patients not on background sulfonylurea (HbA1c b8.0%: 5.4%,
4.1%, and 3.6%; HbA1c 8.0%–b 9.0%: 2.3%, 4.3%, and 0.8%; and HbA1c
≥9.0%: 1.9%, 4.7%, and 0% with canagliﬂozin 100 and 300 mg and
placebo, respectively). The overall incidence of documented hypogly-
cemia episodes was higher across HbA1c subgroups in patients on
background sulfonylurea, compared with patients not on background
sulfonylurea (HbA1c b8.0%: 35.1%, 42.1%, and 18.4%; HbA1c 8.0%–b9.0%:
23.5%, 19.6%, and 16.0%; and HbA1c ≥9.0%: 15.6%, 17.2%, and 6.7% with
canagliﬂozin 100 and 300 mg and placebo, respectively).
The incidence of AEs was generally similar across subgroups by
known T2DM duration, with slight differences in patients with longer
versus shorter known duration of T2DM (Table 4). The incidence of
AEs leading to discontinuation was slightly higher in patients
receiving canagliﬂozin 300 mg in the 5–b10 year subgroup and with
both canagliﬂozin doses in the ≥10 year subgroup compared withTable 4
Summary of overall safety and speciﬁc AEs in subgroups by known duration of T2DM.
T2DM duration b5 y T2DM d
Patients, n (%) PBO
(n = 253)
CANA 100 mg
(n = 341)
CANA 300 mg
(n = 342)
PBO
(n = 20
Any AE 143 (56.5) 204 (59.8) 179 (52.3) 125 (62
AEs leading to discontinuation 7 (2.8) 13 (3.8) 5 (1.5) 6 (3.0
AEs related to study druga 26 (10.3) 68 (19.9) 63 (18.4) 28 (14
Serious AEs 4 (1.6) 11 (3.2) 6 (1.8) 7 (3.5
Deaths 1 (0.4) 1 (0.3) 1 (0.3) 0
Genital mycotic infection
Maleb,c 1 (0.8) 3 (1.8) 4 (2.4) 0
Femaled,e 5 (4.1) 19 (10.7) 14 (7.9) 5 (5.1
UTI 10 (4.0) 22 (6.5) 12 (3.5) 8 (4.0
Osmotic diuresis–related AEsf 2 (0.8) 18 (5.3) 12 (3.5) 0
Volume depletion–related AEsg 0 2 (0.6) 2 (0.6) 1 (0.5
AE, adverse event; PBO, placebo; CANA, canagliﬂozin; UTI, urinary tract infection.
a Possibly, probably, or very likely related to study drug, as assessed by investigators.
b T2DM duration b5 years: PBO, n = 130; CANA 100 mg, n = 164; CANA 300 mg, n = 16
n = 124; T2DM duration ≥10 years: PBO, n = 102; CANA 100 mg, n = 112; CANA 30
c Including balanitis, balanitis candida, balanoposthitis, and genital infection fungal.
d T2DM duration b5 years: PBO, n = 123; CANA 100 mg, n = 177; CANA 300 mg, n = 1
n = 121; T2DM duration ≥10 years: PBO, n = 91; CANA 100 mg, n = 116; CANA 300
e Including genital infection fungal, vaginal infection, vulvitis, vulvovaginal candidiasis, v
f Including dry mouth, micturition urgency, nocturia, pollakiuria, polydipsia, polyuria, th
g Including blood pressure decreased, dehydration, dizziness postural, hypotension, orthplacebo; the incidence of AE-related discontinuations was low and
similar across treatment groups in patients with known T2DM
duration b5 years. A dose-dependent increase in the incidence of
AEs related to the study drug was observedwith canagliﬂozin 100 and
300 mg compared with placebo across subgroups by known T2DM
duration. Across subgroups by known T2DM duration, an increased
incidence of male and female genital mycotic infections was observed
with canagliﬂozin 100 and 300 mg compared with placebo, respec-
tively, and was highest in the patients with the longest known T2DM
duration. Across subgroups by known T2DM duration, the incidence
of osmotic diuresis–related AEs was higher in patients treated with
canagliﬂozin 100 and 300 mg compared with placebo. A low and
similar incidence of volume depletion–related AEs was seen across
subgroups. In patients not on background sulfonylurea, the incidence
of documented hypoglycemia episodes (≤3.9 mmol/L) was similar
across treatment groups regardless of known T2DM durationuration 5–b10 y T2DM duration ≥10 y
0)
CANA 100 mg
(n = 264)
CANA 300 mg
(n = 245)
PBO
(n = 193)
CANA 100 mg
(n = 228)
CANA 300 mg
(n = 247)
.5) 158 (59.8) 148 (60.4) 116 (60.1) 139 (51.0) 167 (67.6)
) 9 (3.4) 13 (5.3) 7 (3.6) 14 (6.1) 12 (4.9)
.0) 50 (18.9) 61 (24.9) 31 (16.1) 53 (23.2) 67 (27.1)
) 7 (2.7) 9 (3.7) 11 (5.7) 10 (4.4) 7 (2.8)
0 0 1 (0.5) 0 0
6 (4.5) 6 (4.8) 1 (1.0) 8 (7.1) 5 (4.3)
) 12 (9.1) 15 (12.4) 0 13 (11.2) 20 (15.3)
) 13 (4.9) 11 (4.5) 8 (4.1) 14 (6.1) 13 (5.3)
19 (7.2) 20 (8.2) 3 (1.6) 19 (8.3) 15 (6.1)
) 2 (0.8) 2 (0.8) 6 (3.1) 6 (2.6) 7 (2.8)
4; T2DM duration 5–b10 years: PBO, n = 102; CANA 100 mg, n = 132; CANA 300 mg,
0 mg, n = 116.
78; T2DM duration 5–b10 years: PBO, n = 98; CANA 100 mg, n = 132; CANA 300 mg,
mg, n = 131.
ulvovaginal mycotic infection, and vulvovaginitis.
irst, and urine output increased.
ostatic hypotension, orthostatic intolerance, presyncope, and syncope.
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≥10 years: 4.2%, 6.8%, and 0.8% with canagliﬂozin 100 and 300 mg
and placebo, respectively). The incidence of documented hypoglyce-
mia episodes was higher with canagliﬂozin 100 and 300 mg
compared with placebo in patients on background sulfonylurea,
with higher risk observed in all treatment groups as known duration
of T2DM increased (b5 years: 17.9%, 17.5%, and 12.9%; 5–b10 years:
25.9%, 22.2%, and 15.4%; and ≥10 years: 35.0%, 42.3%, and 16.4% with
canagliﬂozin 100 and 300 mg and placebo, respectively).
4. Discussion
Findings from this post hoc analysis demonstrated that canagliﬂozin
improved glycemic control in patients with T2DM across a range of
baseline HbA1c and known duration of T2DM, including those with
lower baseline HbA1c and longer T2DM duration. Over 26 weeks,
patientswith higher baselineHbA1c had larger reductions inHbA1cwith
canagliﬂozin 100 and 300 mg than those with lower baseline HbA1c.
This is consistent with previous reports for canagliﬂozin and other
non-insulin glucose-lowering agents, including sulfonylureas, metfor-
min, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like
peptide-1 receptor agonists, andotherSGLT2 inhibitors (Bloomgardenetal.,
2006; Esposito et al., 2014; Zhang, Feng, List, Kasichayanula,&Pﬁster, 2010),
that demonstrated a progressively greater HbA1c-lowering effect as
baseline HbA1c increased. Furthermore, more patients had HbA1c b7.0%
at Week 26 with canagliﬂozin compared with placebo, particularly
among those with a lower HbA1c at baseline.
Canagliﬂozin 100 and 300 mg provided similar glycemic efﬁcacy in
patients regardless of known T2DMduration, which is representative of
various stages of T2DM. This suggests that the likelihood of achieving
glycemic goals with canagliﬂozin is similar across the spectrum of
T2DM, even in those with longer duration of T2DM who may have
greater impairment of beta-cell function. However, this is not surprising
given themechanism of action of canagliﬂozin, which is independent of
beta-cell function, and a previous report that the glycemic efﬁcacy of
canagliﬂozin is largely independent of beta-cell function or insulin
sensitivity (Matthews, Zinman, Tong, Meininger, & Polidori, 2014).
Canagliﬂozin was generally well tolerated across the baseline HbA1c
and known duration of T2DM subgroups, with a safety proﬁle similar to
that seen in the overall population (Usiskin et al., 2014). Of note,
patients in the highest baseline HbA1c subgroup who received
canagliﬂozin 100 or 300 mg reported more female genital mycotic
infections and osmotic diuresis–related AEs comparedwith those in the
lower HbA1c subgroups. The increase in genital mycotic infections with
canagliﬂozin versus placebo was not strictly baseline HbA1c- or
dose-dependent, suggesting a threshold of UGE associated with genital
mycotic infections. Other factors, such as prior history of genitalmycotic
infection or being uncircumcised, may be related to the increased
incidence of genital mycotic infections with canagliﬂozin compared
with placebo (Nyirjesy et al., 2014). Consistent with the overall
population (Usiskin et al., 2014), the incidence of documented
hypoglycemia episodes (≤3.9 mmol/L) was higher in patients on
background sulfonylurea, with increases seen across groups with
increasing known duration of T2DM.
This analysis is strengthened by the inclusion of a large, general
population of patients with T2DM with diverse baseline characteris-
tics. A limitation of this analysis was the lack of prespeciﬁed statistical
testing across subgroups based on baseline HbA1c and known
duration of T2DM; however, the inclusion of 95% CIs provides
descriptive comparisons for treatment with both canagliﬂozin doses
and placebo. In addition, longer-term efﬁcacy and safety analyses of
canagliﬂozin in subgroups based on HbA1c and known duration of
T2DMwould be beneﬁcial to understand the durability of beneﬁts and
risks associated with canagliﬂozin treatment.
Because the efﬁcacy of some T2DM treatments may be impacted
by baseline patient characteristics, consideration of the potentialimpact of these factors may be beneﬁcial as part of the shared
decision-making process with patients regarding optimal T2DM
treatment options. Findings from this analysis suggest that canagli-
ﬂozin may be a therapeutic option in patients with T2DM across a
range of baseline HbA1c levels and different stages of T2DM.
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